Skip to main content

Table 1 Monoclonal antibodies

From: A review of ocular adverse events of biological anti-TNF drugs

DrugEtanercept (Enbrel)Infliximab (Remicade)Adalimumab (Humira)Golimumab (Simponi, Simponi Aria)Certolizumab (Cimzia)
Structure and mechanism of actionTNFR2 ectodomain fused to IgG1 binds TNF-α and TNF-βChimeric murine-human IgG1 that binds TNF-αFully humanized IgG1 that binds TNF-αFully humanized IgG1 that binds TNF-αHumanized PEGylated Fab that binds TNF-α
IndicationsRA, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, and juvenile idiopathic arthritisRA, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, idiopathic pulmonary fibrosis, ulcerative colitis, and Crohn’s diseaseRA, psoriatic arthritis, ankylosing spondylitis, spondyloarthritis, juvenile idiopathic arthritis, uveitis (intermediate, posterior, panuveitis), plaque psoriasis, hidradenitis suppurativa, ulcerative colitis, and Crohn’s diseaseRA, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitisRA, psoriatic arthritis, ankylosing spondylitis, spondyloarthritis, and Crohn’s disease
Reported ocular side effectsUveitis, scleritis, ON, and ocular myositisUveitis, ON, and endophthalmitisUveitis, ON, endophthalmitis, corneal infiltrates, retinal toxicity, and ophthalmoplegiaONON
\